Apellis Pharmaceuticals Inc. (APLS) and Crinetics Pharmaceuticals Inc. (NASDAQ:CRNX) Comparison side by side

Both Apellis Pharmaceuticals Inc. (NASDAQ:APLS) and Crinetics Pharmaceuticals Inc. (NASDAQ:CRNX) compete on a level playing field in the Biotechnology industry. We will evaluate their performance with regards to profitability, analyst recommendations, risk, institutional ownership, dividends, earnings and valuation.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Apellis Pharmaceuticals Inc. 22 0.00 N/A -2.77 0.00
Crinetics Pharmaceuticals Inc. 23 227.73 N/A -1.27 0.00

We can see in table 1 the earnings per share (EPS), gross revenue and valuation of Apellis Pharmaceuticals Inc. and Crinetics Pharmaceuticals Inc.

Profitability

Table 2 represents Apellis Pharmaceuticals Inc. (NASDAQ:APLS) and Crinetics Pharmaceuticals Inc. (NASDAQ:CRNX)’s return on equity, net margins and return on assets.

Net Margins Return on Equity Return on Assets
Apellis Pharmaceuticals Inc. 0.00% -77.1% -60.8%
Crinetics Pharmaceuticals Inc. 0.00% -27% -20.8%

Liquidity

The Current Ratio and a Quick Ratio of Apellis Pharmaceuticals Inc. are 15.2 and 15.2. Competitively, Crinetics Pharmaceuticals Inc. has 18 and 18 for Current and Quick Ratio. Crinetics Pharmaceuticals Inc.’s better ability to pay short and long-term obligations than Apellis Pharmaceuticals Inc.

Analyst Ratings

Apellis Pharmaceuticals Inc. and Crinetics Pharmaceuticals Inc. Recommendations and Ratings are available in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Apellis Pharmaceuticals Inc. 0 0 1 3.00
Crinetics Pharmaceuticals Inc. 0 0 1 3.00

$45 is Apellis Pharmaceuticals Inc.’s average price target while its potential upside is 57.89%. On the other hand, Crinetics Pharmaceuticals Inc.’s potential upside is 150.63% and its average price target is $40. The results provided earlier shows that Crinetics Pharmaceuticals Inc. appears more favorable than Apellis Pharmaceuticals Inc., based on analyst view.

Insider and Institutional Ownership

Roughly 66.1% of Apellis Pharmaceuticals Inc. shares are owned by institutional investors while 97.6% of Crinetics Pharmaceuticals Inc. are owned by institutional investors. 1.6% are Apellis Pharmaceuticals Inc.’s share owned by insiders. Competitively, insiders own roughly 5.65% of Crinetics Pharmaceuticals Inc.’s shares.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Apellis Pharmaceuticals Inc. -3.62% 9.83% 49.36% 105.82% 57.53% 111.75%
Crinetics Pharmaceuticals Inc. -16.58% -18.91% -21.15% -18.03% -20.72% -32.38%

For the past year Apellis Pharmaceuticals Inc. has 111.75% stronger performance while Crinetics Pharmaceuticals Inc. has -32.38% weaker performance.

Summary

Crinetics Pharmaceuticals Inc. beats Apellis Pharmaceuticals Inc. on 7 of the 8 factors.

Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutic compounds for autoimmune and inflammatory diseases. Its lead product candidates include APL-2 and APL-1, to treat paroxysmal nocturnal hemoglobinuria, geographic atrophy, intermediate age-related macular degeneration, and chronic obstructive pulmonary disease. The company develops APL-2 for subcutaneous injection, which is an injection into the tissue under the skin, and for intravitreal injection that is an injection into the eye, as well as APL-1 for inhaled administration. Apellis Pharmaceuticals, Inc. was founded in 2009 and is based in Crestwood, Kentucky.

Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is CRN00808, an oral selective nonpeptide somatostatin receptor type 2 biased agonist, which is in Phase I clinical trials used for the treatment of acromegaly. The company is also developing CRN02481, an oral selective nonpeptide somatostatin type 5 receptor agonist used for the treatment of congenital hyperinsulinism; and CRN01941, an oral, selective nonpeptide sst2 biased agonist designed for the treatment of neuroendocrine tumors. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.